|Bid||170.60 x 200|
|Ask||172.75 x 300|
|Day's Range||170.77 - 173.92|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.23|
|Dividend & Yield||4.60 (2.65%)|
|1y Target Est||N/A|
Can AbbVie's top-notch clinical pipeline overcome the company's hefty risk profile?
Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism